Background. Hyperthermic isolated limb perfusion (HILP) or isolated limb infusion (ILI) are well-accepted regional chemotherapy techniques for in-transit melanoma of extremity. The role and efficacy of repeat regional chemotherapy for recurrence and which salvage procedure is better remains debatable. We aimed to compare toxicities and clinical outcomes by procedure types and the sequence. Methods. Data from 44 patients, who underwent repeat HILPs or ILIs from 3 institutions beginning 1997 to 2010, were retrospectively reviewed. Regional toxicity assessed by Wieberdink grade, systemic toxicity assessed by serum creatine phosphokinase level, length of hospital stay (LOS), response rates at 3 months after the procedure, and time to in-field progression (TTP) were analyzed. Results. Of 44 patients, 46% were men and 54% women with a median age of 66 (range 29-85) years at diagnosis. The median follow-up was 21.4 (range 4-153) months. Of 70 ILIs and 28 HILPs, the following groups were identified: group A, ILI ? ILI (n = 25); group B, ILI ? HILP (n = 10); group C, HILP ? ILI (n = 12); and group D, HILP ? HILP (n = 3). The comparison of Wieberdink grade, serum creatine phosphokinase level, LOS, and response rate between procedures (HILP vs. ILI), between sequence (initial vs. repeat), and among their interactions showed no statistically significant differences. TTP after initial procedure did not differ between HILP and ILI (P = 0.08), and no survival difference was seen (P = 0.65) when TTP after repeat procedure was compared. Conclusions. Most patients tolerated repeat regional chemotherapy without increased toxicity or LOS. No statistical difference in clinical outcomes was noted when comparing repeat procedures, even though repeat HILPs showed higher complete response compared to repeat ILIs.
response rate between procedures (HILP vs. ILI), between sequence (initial vs. repeat), and among their interactions showed no statistically significant differences. TTP after initial procedure did not differ between HILP and ILI (P = 0.08), and no survival difference was seen (P = 0.65) when TTP after repeat procedure was compared.
Conclusions. Most patients tolerated repeat regional chemotherapy without increased toxicity or LOS. No statistical difference in clinical outcomes was noted when comparing repeat procedures, even though repeat HILPs showed higher complete response compared to repeat ILIs.
Hyperthermic isolated limb perfusion (HILP), first reported in 1958, and isolated limb infusion (ILI) developed in the early 1990 s have allowed the regional delivery of cytotoxic agents (often melphalan) to patients with unresectable in-transit metastases confined to extremities from melanoma at 10-fold higher than the systemic dose. [1] [2] [3] For patients with locally advanced melanoma in extremities, the administration of high-dose regional chemotherapy via HILP or ILI has proven to be efficacious in locoregional disease control, with good overall response rates (ORR). 4 In addition, compared to local treatments, delivery of regional chemotherapy to the affected extremity isolated from the systemic circulation treats the whole area at risk of recurrence by theoretically eradicating clinically occult microscopic disease. 5, 6 Single-institution complete response (CR) rates usually exceed 50% for HILP with melphalan alone with ORR approaching 90%. 7, 8 Similar response rates have not been uniformly reported with ILI, which seems to have CR rates ranging 30-38% and ORR ranging 60-70% with less severe regional and systemic toxicity than HILP. However, the locoregional recurrence rates can range 22-100% even after CR from HILP and ILI. [7] [8] [9] [10] [11] [12] An appropriate management of these patients who develop locoregional recurrence after good initial response to the regional therapy is challenging, and no clear treatment recommendations exist. Although there is currently no consensus on the most appropriate management of these recurrences, a few centers have suggested that favorable results can be achieved utilizing a repeat regional therapy if it is planned at the time of the initial procedure or utilized at the time of regional disease progression. 6, [13] [14] [15] [16] Thus, the treatment approach for this specific group of patients-the decision to continue with the same treatment modality (HIL-P ? HILP, ILI ? ILI) or proceed with alternative therapy (HILP ? ILI, ILI ? HILP)-can be vague. Furthermore, whether a difference exists for patients who undergo ILI after prior HILP or HILP after prior ILI in regional toxicity or response rates is uncertain. Given these observations, the goal of this study was to examine our multi-institutional experience in order to develop a more standardized treatment recommendation for patients who experience locoregional recurrence after regional chemotherapy.
PATIENTS AND METHODS
After institutional review board approval, a multi-institutional retrospective review from three institutions was performed on patients who underwent at least two regional chemotherapy procedures from 1997 to 2010. Eligible patients included those who underwent a repeat HILP or ILI for extremity melanoma (American Joint Committee on Cancer disease stage IIIB or IIIC). We collected patient variables such as gender and age at diagnosis, and operative variables such as type of procedure, ischemic time, tourniquet time, peak temperature, dose calculation of melphalan, use of papaverine, and number of treatments. The time to in-field progression (TTP) was defined as the time from the procedure to the time of locoregional disease progression. In-field progression was considered as any recurrent or progressing disease from the primary melanoma site to the level of next nodal basin. Considering the combination of procedures and their sequences, the patients were divided into four groups: group A (ILI ? ILI), group B (ILI ? HILP), group C (HILP ? ILI), and group D (HILP ? HILP).
Procedure Techniques: ILI Versus HILP
A detailed description of ILI technique has previously been reported and documented in the literature. 17, 18 Most patients received dose-corrected melphalan based on the ideal body weight. HILP was performed by means of a standard technique under general anesthesia, as previously described.
1,2,14
Toxicities and Outcomes
The regional toxicity was determined by close physical examination of the affected extremity and scored according to Wieberdink toxicity grade. 19 Severe regional toxicity was defined as Wieberdink grade CIV. Systemic toxicity was assessed by monitoring peak serum creatine phosphokinase (CPK) level. 17 The serum CPK level was measured daily, and patients were discharged home after the peak CPK level was documented and showed a decreasing trend toward a normal level.
The length of stay (LOS) was defined from the day of procedure to the day of discharge; follow-up duration was defined from the day of initial procedure to the day of last clinic visit or date of death. The response rate was determined 3 months after the procedure and recorded as CR, partial response (PR), stable disease, or progression of disease according to Response Evaluation Criteria in Solid Tumors (RECIST) modified for cutaneous lesions. 17 
Statistical Analysis
Statistical analysis was performed by SAS software, version 9.2 (SAS, Cary, NC). A two-sided P value of B0.05 was considered statistically significant. Box plots were used to visualize the data distribution. For patients whose disease progressed after initial HILP or ILI, TTP was evaluated by the two-sample Wilcoxon exact test. TTP after repeat procedures was compared by the Kaplan-Meier method and the log rank test.
RESULTS

Patient and Procedure Characteristics
Of the 44 patients in our study, 20 (46%) were men. The median age at the time of initial diagnosis was 66 (range 29-85) years. The median follow-up was 21.4 (range 4-153) months. All patients had in-transit disease or recurrent disease at the time of presentation. Most procedures (86%) were performed for lower extremity disease. A total of 98 procedures were performed (28 HILPs and 70 ILIs); 37 patients (84%) had 2 procedures, 4 patients (9%) had 3 procedures, and 3 patients (6.8%) had 4 procedures ( Table 1 ). The overall median duration between initial and repeat procedure was 6.6 (range 2-74) months. The mediation duration between initial and repeat procedure for group A (n = 25) was 6 months, group B (n = 10) 6 months, group C (n = 12) and 24 months, and group D (n = 3) 31 months. The ORR for all 98 procedures at 3 months after treatment was 38% (CR 21%, PR 16%).
Preoperative and Intraoperative Parameters
Cytotoxic agents were circulated for 60 min during HILP and 30 min during ILI. All patients received the standard dose of melphalan at the time of procedure. Fiftyfour ILIs (77%) were performed with actinomycin D in addition to melphalan. Sixteen ILIs were also part of a clinical trial that used systemic ADH-1 or sorafenib in combination with melphalan. Papaverine was provided in 51% of procedures. The mean ischemic time (ILI only) was 65 (range 45-110) minutes. The peak temperature was 39°C (range 37-41°C) for ILIs and was 39.9°C (range 39-42°C) for HILPs.
Regional Toxicity by Wieberdink Toxicity Grade
The most common regional toxicity experienced was Wieberdink grade II after ILI and Wieberdink grade III after HILP. For HILPs performed, 11% of patients had Wieberdink grade IV toxicity, and 1 patient (3.5%) had Wieberdink grade V toxicity requiring an amputation. Of the 70 ILIs performed, only 1 patient (\1%) had Wieberdink grade IV toxicity, and no patient undergoing ILI had a grade V toxicity. Even though it appears that HILPs are associated with an increased incidence of severe regional toxicity (Wieberdink grade CIV) compared to ILIs, no statistical difference was detected (P = 0.08), likely as a result of the small sample size of the groups. Similarly, there was no difference in regional toxicity between initial and repeat procedure (P = 0.25) or among different sequence of procedures (P = 0.09) (Fig. 1A) .
Systemic Toxicity by Serum CPK Level
Serum CPK was measured daily and was used to monitor systemic toxicity. The median peak CPK was 214 (range 37-11,674) U/L for ILI and 616 (range 129-3945) U/L for HILP (P = 0.56). There was no significant difference in peak CPK between initial and repeat procedure (P = 0.98) or among different sequence of procedures (P = 0.71) (Fig. 1B) . 
Length of Stay (LOS)
The median LOS after ILI was 7 days and was 6 days for HILP (P = 0.23). There was no significant difference in LOS among four subgroups (ILI ? ILI, ILI ? HILP, HILP ? HILP, HILP ? ILI) (P = 0.69). When LOS was evaluated in terms of interaction between the procedure type and sequence, these variables did not influence the patient's LOS after repeat procedures (P = 0.71) (Fig. 1C) .
Overall Response Rates (ORR)
The ORR for ILI (n = 70) was 33% (17% CR and 16% PR), however the ORR for HILP (n = 28) was higher, at 49.9% (32% CR and 18% PR). When comparing the CR rates and ORR between ILI and HILP, no significant difference was noted for either CR or ORR (P = 0.17 and P = 0.12, respectively). When CR rates were compared on the basis of initial versus repeat procedure or interaction between procedure type and its sequence, no statistical difference was noted (P = 0.43 and P = 0.64, respectively). Similarly, when ORR was compared on the basis of initial versus repeat procedure, or between procedure type and sequence, there was no significant difference (P = 0.82 and P = 0.70, respectively). The response rates appeared to be equivalent for both ILIs and HILPs when compared as a group or when performed as either initial or repeat procedure.
Time to In-Field Progresson (TTP)
The median time to locoregional progression after initial ILI was 3 months, compared to 6.4 months after initial HILP (P = 0.08) ( Fig. 2A) . After repeat ILI or HILP, the median TTP was 3 vs. 4.1 months, respectively. When comparing overall outcome after repeat ILI or HILP, the shorter TTP after ILI did not result in a significant survival difference as there was no statistical difference in survival between groups on log rank analysis (P = 0.65) (Fig. 2B) .
Subgroup Analysis
We further investigated whether having an ILI as the initial procedure before repeat ILI or HILP produced a statistically significant difference in clinical outcome measured by LOS, toxicity, and response rates. When comparing these variables between group A (ILI ? ILI) and group B (ILI ? HILP) ( Table 2) , no significant difference in LOS and regional or systemic toxicity were noted between the two groups. However, patients in group B who underwent an initial ILI followed by HILP for recurrence showed an improved response rate with 70% ORR and 50% CR rate compared to patients in group A who underwent a repeat ILI with 40% ORR and 24% CR rate although the difference was not significant (P = 0.11). Also, patients in group D, who underwent initial and repeat HILP, obtained 100% ORR with 66% CR rate after the repeat procedure. Although we were unable to fully evaluate, other than by means of descriptive statistics, the impact of having HILP as the initial procedure followed by a repeat ILI (group C) as a result of the excessive amount of missing variables, a repeat ILI after an initial HILP produced the lowest response rate in our study. Although these results admittedly represent a small number of highly selected patients and were not statistically significant, there did appear to be an identifiable trend observed for patients in group B (ILI ? HILP) and group D (HILP ? HILP) in that repeat HILP after initial ILI or initial HILP was associated with a better response rate than repeat ILI. One must keep in mind the small sample size, different duration of response, type of treatment, and heterogeneity of therapy when comparing these groups as major limitations of the study, and as a result of the small groups, there is a lack of power to detect differences.
DISCUSSION
Even though many exciting discoveries have recently been made in the field of melanoma, increasing the armamentarium for adjuvant treatment options such as pegylated interferon-a2b, vemurafenib, ipilimumab, and combination therapies, regional chemotherapy still remains an attractive option for extensive in-transit or bulky recurrent melanoma not amenable to complete surgical excisions and for patients who refuse or are not candidates for systemic therapy. 18 However, even though regional chemotherapy for advanced melanoma confined to the extremities is well accepted, the treatment approach has not been standardized. 20 In the current study, we reviewed the clinical outcomes from different sequence of repeat regional therapies to evaluate an optimal treatment approach for patients who experience recurrence after the initial regional therapy.
An algorithm that uses ILI for the initial treatment approach to in-transit disease or local recurrence was previously proposed on the basis of a multi-institutional experience. 21 Here we focus on the approach to patients with locoregional recurrence or progression after initial regional chemotherapies (ILI or HILP) (Fig. 3) . Our proposed approach to the initial and recurrent regional intransit disease is as follows: As our data demonstrate, because there is no statistically significant difference in toxicity, LOS, and response rates between HILP and ILI, it is reasonable to offer ILI as the initial regional chemotherapy of choice because of its less complex and less invasive nature when compared to HILP. For a patient with high-volume, bulky disease or with nodal disease, HILP may be considered as the initial procedure of choice because a nodal dissection is part of the exposure for the root of the extremity vasculature for HILP. When a patient presents with small-volume recurrences, which are amenable to complete surgical excision after initial regional therapy, resection should be performed to render the patient disease-free. When a patient presents with unresectable recurrence after the initial procedure, the repeat procedure should be determined according to the pattern of recurrence, duration of response, and type of initial procedure. For example, if the patient continues to experience a progression of disease or recurrence within 3 months from an initial ILI, the patient should undergo HILP as the next procedure rather than a repeat ILI because HILP appears to result in a higher response rate (group B), as seen in Table 2 . For a patient who had HILP as the initial procedure, a repeat regional therapy with an ILI is unlikely to improve the response rate because this rapid progression of disease after HILP probably suggests aggressive tumor biology. Of the 4 subgroups we evaluated, the patients who underwent a repeat ILI after a failed HILP showed lowest ORR of 18%. These patients may benefit from a clinical trial with a protocol-based ILI that uses an alternative intra-arterial chemotherapeutic agent such as temozolomide, systemic chemotherapy, or a combination of the two. However, if a patient had a CR or statistically significant PR after the initial ILI or HILP with good duration of response (at least [3 months before recurrence or progression), then it may be reasonable to consider either a repeat ILI or HILP or a protocol-based ILI. If disease recurs after the repeat regional therapy, the patient can follow the recurrent disease pathway in the proposed algorithm in Fig. 3 . Clinical trials for patients with unresectable melanoma of extremity (direct intralesional injection, systemic therapies, protocol-based regional therapies) should also be considered early in the management of the patient with in-transit melanoma. Our current follow-up schedule for these patients (after ILI or HILP, regardless of status as an initial or repeat procedure) includes clinic visits every 3 months with a physical examination and a whole-body PET or CT scan for the first 2 years, then every 4 months with scans for year 3. We recommend follow-up scans every 6 months during years 4 and 5. Once the patient is more than 5 years out from the last recurrence, a yearly physical examination and wholebody imaging is suggested.
For patients who present with advanced melanoma (intransit disease) confined to an extremity (stage IIIb or IIIc), studies have shown that the burden of disease and status of the regional nodal basin are reliable predictors of response rates to the regional therapy and overall survival. On the other hand, a good response from regional chemotherapies does not affect either disease-free or overall survival. [22] [23] [24] Thus, it is important to explore different treatment options and alternatives to melphalan to improve survival of these patients in addition to improving quality of life. Realizing the importance of alternative therapeutic options, active trials and research are being conducted to augment antitumor effect delivered via regional chemotherapy. For example, the animal study with ILI that used temozolomide showed encouraging tumor responses when compared to systemic temozolomide and ILI with melphalan. 25 The efficacy and safety of temozolomide as an alternative to melphalan is currently being examined in a phase I multiinstitutional trial. The idea of combination therapy utilizing both the regional delivery of high-dose therapeutic agent and a systemic agent targeting a specific molecular pathway to enhance regional antitumor effect is also being explored. Some of our patients were enrolled onto the research investigating the role of ADH-1 and sorafenib as systemic agents to increase the effect of melphalan. In the phase I trial, the systemic ADH-1 used in conjunction with melphalan via ILI produced a CR rate of 50% with no dose-limiting toxicities. 26 Even though the phase II trial recently published showed CR rate of 38% with the TTP of 4.6 months without statistically significant difference compared to standard ILI, it is exciting to see different treatment options being explored with systemic targeting agents to improve drug sensitivity to tumors. 27 
FIG. 3
Proposed treatment algorithm for recurrent extremity melanoma after regional chemotherapy Furthermore, the potential role of ipilimumab, a recently approved immunomodulator, in the adjuvant setting is also being investigated in phase III trial for stage III patients (EORTC 18071), and it may play an important role in our patient population in the future.
In conclusion, repeat regional chemotherapy is a practical option for a patient with recurrence after an initial regional therapy. Even though our study was not sufficiently powered to show the statistical difference in response rates for different subgroups analyzed, HILP may be more suitable as a repeat procedure, especially if the response to the initial ILI was poor. We can also conclude that for a patient whose disease responds poorly to the initial HILP, an alternative treatment method such as systemic therapy, trial-based local injections, or repeat regional therapy with a nontraditional agent on protocol should be considered rather than the standard melphalanbased therapy. The patient should be counseled on risks, benefits, and alternatives to each procedure. Ultimately, choosing the most appropriate method of treatment needs to be individualized in a multidisciplinary setting, exploiting all available options, including looking at repeat perfusions, systemic therapies, and clinical trials taking into account all the current advances in the armamentarium in melanoma treatment.
